Published in J Virol on March 01, 1998
The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol (1999) 1.76
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A (2005) 1.72
Conformational changes in the hepatitis B virus core protein are consistent with a role for allostery in virus assembly. J Virol (2009) 1.42
Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol (2000) 1.41
Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen. J Virol (1999) 1.39
Hepatitis B virus core gene mutations which block nucleocapsid envelopment. J Virol (2000) 1.31
Hepatitis B virus capsid assembly is enhanced by naturally occurring mutation F97L. J Virol (2004) 1.29
Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins. J Virol (2003) 1.10
A defective interference-like phenomenon of human hepatitis B virus in chronic carriers. J Virol (1998) 1.07
Replication advantage and host factor-independent phenotypes attributable to a common naturally occurring capsid mutation (I97L) in human hepatitis B virus. J Virol (2002) 1.06
Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation. J Virol (1999) 0.98
Virologic characteristics of hepatitis B virus in patients infected via maternal-fetal transmission. World J Gastroenterol (2008) 0.83
Increased expression of Gp96 by HBx-induced NF-κB activation feedback enhances hepatitis B virus production. PLoS One (2013) 0.82
Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion. J Gastroenterol (2007) 0.82
Replication of naturally occurring woodchuck hepatitis virus deletion mutants in primary hepatocyte cultures and after transmission to naive woodchucks. J Virol (2001) 0.79
HBV polymerase overexpression due to large core gene deletion enhances hepatoma cell growth by binding inhibition of microRNA-100. Oncotarget (2016) 0.78
Inhibition of infection spread by co-transmitted defective interfering particles. PLoS One (2017) 0.75
Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell (1982) 16.71
The hepatitis B virus. Nature (1985) 8.71
Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature (1997) 7.32
Defective viral particles and viral disease processes. Nature (1970) 7.24
A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J (1990) 5.74
Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature (1990) 5.68
The mechanism of RNA recombination in poliovirus. Cell (1986) 5.35
The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol (1990) 5.19
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell (1992) 4.72
Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol (1990) 4.57
Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy. Nature (1997) 4.35
Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein. J Virol (1990) 4.16
Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J (1992) 3.78
An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol (1993) 3.72
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A (1990) 3.25
Coronavirus: organization, replication and expression of genome. Annu Rev Microbiol (1990) 3.20
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase. Proc Natl Acad Sci U S A (1996) 2.97
Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. EMBO J (1997) 2.91
A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids. J Virol (1989) 2.72
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol (1996) 2.68
RNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication. J Virol (1992) 2.42
Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol (1994) 2.41
Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol (1989) 2.27
Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol (1987) 2.25
Effects of insertional and point mutations on the functions of the duck hepatitis B virus polymerase. J Virol (1990) 2.22
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis. J Virol (1996) 2.07
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol (1995) 1.71
Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol (1993) 1.71
Carboxy-terminal truncations of the HBV core protein affect capsid formation and the apparent size of encapsidated HBV RNA. Virology (1993) 1.62
Hepatitis B virus transcript produced by RNA splicing. J Virol (1989) 1.52
Expression of the P-protein of the human hepatitis B virus in a vaccinia virus system and detection of the nucleocapsid-associated P-gene product by radiolabelling at newly introduced phosphorylation sites. Nucleic Acids Res (1992) 1.50
In vitro propagation of human hepatitis B virus in a rat hepatoma cell line. Proc Natl Acad Sci U S A (1989) 1.50
An "attenuator domain" is sandwiched by two distinct transactivation domains in the transcription factor C/EBP. Mol Cell Biol (1991) 1.44
Preferred translation of human hepatitis B virus polymerase from core protein- but not from precore protein-specific transcript. J Virol (1990) 1.43
Tight clustering of human hepatitis B virus integration sites in hepatomas near a triple-stranded region. J Virol (1987) 1.42
Defective hepatitis B virus particles are generated by packaging and reverse transcription of spliced viral RNAs in vivo. J Virol (1991) 1.41
Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest (1993) 1.38
Core antigen mutations of human hepatitis B virus in hepatomas accumulate in MHC class II-restricted T cell epitopes. Virology (1995) 1.32
Identification of a doubly spliced viral transcript joining the separated domains for putative protease and reverse transcriptase of hepatitis B virus. J Virol (1989) 1.31
Pregenomic RNA encapsidation analysis of eleven missense and nonsense polymerase mutants of human hepatitis B virus. J Virol (1991) 1.30
Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol (1997) 1.27
Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J Virol (1996) 1.25
Detection of pre-C and core region mutants of hepatitis B virus in chronic hepatitis B virus carriers. J Clin Invest (1991) 1.21
Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. J Clin Invest (1996) 1.20
Defective mutants of hepatitis B virus in the circulation of symptom-free carriers. Jpn J Exp Med (1987) 1.16
Characterization of a cis element required for packaging and replication of the human hepatitis B virus. Virology (1992) 1.09
Infection initiated by the RNA pregenome of a DNA virus. J Virol (1991) 1.09
A defective interference-like phenomenon of human hepatitis B virus in chronic carriers. J Virol (1998) 1.07
The mechanism of natural occurrence of two closely linked HBV precore predominant mutations. Virology (1995) 1.06
Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol (1997) 0.96
Specific deletions in the hepatitis B virus core open reading frame in patients with chronic active hepatitis B. J Med Virol (1993) 0.96
Comparison of envelope and precore/core variants of hepatitis B virus (HBV) during chronic HBV infection. Virology (1993) 0.96
Accumulation and persistence of hepatitis B virus core gene deletion mutants in renal transplant patients are associated with end-stage liver disease. Hepatology (1996) 0.94
Conserved cysteines of the hepatitis B virus core protein are not required for assembly of replication-competent core particles nor for their envelopment. Virology (1992) 0.93
Evolution of the hepatitis B virus gene during chronic infection in seven patients. J Med Virol (1994) 0.93
A host factor that binds near the termini of hepatitis B virus pregenomic RNA. J Virol (1996) 0.91
Variations of hepatitis B virus precore/core gene sequence in acute and fulminant hepatitis B. Dig Dis Sci (1994) 0.89
Hepatitis B virus C gene heterogeneity in a familial cluster of anti-HBc negative chronic carriers. J Med Virol (1994) 0.89
Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. Gastroenterology (1996) 0.86
Status of hepatitis B virus DNA in hepatocellular carcinoma: a study based on paired tumor and nontumor liver tissues. J Med Virol (1988) 0.84
Naturally occurring core-gene-defective hepatitis B viruses. J Gen Virol (1995) 0.82
Comparison of pre-core/core hepatitis B virus region in liver tissue and serum from patients with chronic hepatitis B infection. J Hepatol (1992) 0.81
A pigment-binding protein essential for regulation of photosynthetic light harvesting. Nature (2000) 6.97
Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell (1982) 6.93
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09
Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A (1979) 5.32
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (1981) 4.72
Keratin cytoskeletons in epithelial cells of internal organs. Proc Natl Acad Sci U S A (1979) 3.45
The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5' termini of viral genomic and antigenomic RNA. Virology (1992) 2.88
Three different human tumor cell lines contain different oncogenes. Cell (1981) 2.77
Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell (1982) 2.22
Trophic conversion of an obligate photoautotrophic organism through metabolic engineering. Science (2001) 2.10
Presentation of striatal hyperintensity on T1-weighted MRI in patients with hemiballism-hemichorea caused by non-ketotic hyperglycemia: report of seven new cases and a review of literature. J Neurol (2001) 2.02
Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release (2001) 1.85
The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol (1999) 1.76
Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci U S A (1983) 1.67
Effects of exogenous arachidonic, eicosapentaenoic, and docosahexaenoic acids on the generation of 5-lipoxygenase pathway products by ionophore-activated human neutrophils. J Clin Invest (1984) 1.65
Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11. Science (1983) 1.58
Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product. J Biol Chem (1984) 1.56
Morphometric variations of the lumbar vertebrae between Chinese and Indian adults. Acta Anat (Basel) (1992) 1.46
Establishment and characterization of a new human hepatocellular carcinoma cell line. In Vitro (1984) 1.43
Preferred translation of human hepatitis B virus polymerase from core protein- but not from precore protein-specific transcript. J Virol (1990) 1.43
Photoprotection in a zeaxanthin- and lutein-deficient double mutant of Arabidopsis. Photosynth Res (2001) 1.42
Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol (2000) 1.41
Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen. J Virol (1999) 1.39
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem (1992) 1.38
Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis. Clin Exp Rheumatol (2005) 1.38
Localization, interaction, and RNA binding properties of the V(D)J recombination-activating proteins RAG1 and RAG2. Immunity (1995) 1.34
Core antigen mutations of human hepatitis B virus in hepatomas accumulate in MHC class II-restricted T cell epitopes. Virology (1995) 1.32
Characterization and genetic analysis of alternatively spliced transcripts of hepatitis B virus in infected human liver tissues and transfected HepG2 cells. J Virol (1991) 1.32
Pregenomic RNA encapsidation analysis of eleven missense and nonsense polymerase mutants of human hepatitis B virus. J Virol (1991) 1.30
Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res (1999) 1.28
Dislocation after total hip arthroplasty. Arch Orthop Trauma Surg (1999) 1.25
Modulation of sperm tail protein tyrosine phosphorylation by pentoxifylline and its correlation with hyperactivated motility. Fertil Steril (1999) 1.24
A frequent, naturally occurring mutation (P130T) of human hepatitis B virus core antigen is compensatory for immature secretion phenotype of another frequent variant (I97L). J Virol (2000) 1.22
Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem (1996) 1.18
Surgical anatomy of the mandibular ramus of the facial nerve in Chinese adults. Acta Anat (Basel) (1991) 1.18
cis rescue of a mutated reverse transcriptase gene of human hepatitis B virus by creation of an internal ATG. J Virol (1990) 1.17
Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol (1999) 1.16
Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol (1997) 1.15
Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene (1993) 1.12
Trinucleotide repeat length and progression of illness in Huntington's disease. J Med Genet (1994) 1.10
A defective interference-like phenomenon of human hepatitis B virus in chronic carriers. J Virol (1998) 1.07
Increased (Na+,K+)-ATPase concentrations in various tissues of rats caused by thyroid hormone treatment. J Biol Chem (1978) 1.07
The mechanism of natural occurrence of two closely linked HBV precore predominant mutations. Virology (1995) 1.06
Subcellular location of XpsD, a protein required for extracellular protein secretion by Xanthomonas campestris pv. campestris. Microbiology (1995) 1.06
Isolation of a complementary DNA fragment of hepatitis C virus in Taiwan revealed significant sequence variations compared with other isolates. Hepatology (1991) 1.05
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res (2000) 1.05
Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol (1999) 1.04
The Drosophila PAR domain protein 1 (Pdp1) gene encodes multiple differentially expressed mRNAs and proteins through the use of multiple enhancers and promoters. Dev Biol (2000) 1.04
The transcription factor HNF1 acts with C/EBP alpha to synergistically activate the human albumin promoter through a novel domain. J Biol Chem (1994) 1.03
Temporal aspects of major viral transcript expression in Hep G2 cells transfected with cloned hepatitis B virus DNA: with emphasis on the X transcript. Virology (1991) 1.02
Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Anticancer Res (1998) 1.01
Mercury-induced conformational changes and identification of conserved surface loops in plasma membrane aquaporins from higher plants. Topology of PMIP31 from Beta vulgaris L. J Biol Chem (1997) 1.00
Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry (1991) 1.00
The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem (1989) 0.99
Radical hysterectomy with pelvic lymph node dissection for treatment of cervical cancer: a clinical review of 954 cases. Gynecol Oncol (1989) 0.96
Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. J Virol (1997) 0.96
Overlapping evolutionary affinities revealed by comparison of amino acid compositions. Proc Natl Acad Sci U S A (1982) 0.96
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res (1994) 0.95
Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res (1996) 0.95
Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest New Drugs (1996) 0.94
Reliability and validity of using a Brief Psychiatric Symptom Rating Scale in clinical practice. J Formos Med Assoc (1990) 0.93
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res (2001) 0.93
Na+,K+-ATPase enzyme units in skeletal muscle from lean and obese mice. Biochem Biophys Res Commun (1978) 0.93
A clinical and anatomical study of the location of the mental foramen in adult Chinese mandibles. Acta Anat (Basel) (1986) 0.93
In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol (1999) 0.92
PDP1, a novel Drosophila PAR domain bZIP transcription factor expressed in developing mesoderm, endoderm and ectoderm, is a transcriptional regulator of somatic muscle genes. Development (1997) 0.92
Comparison of various methods of processing human cryopreserved-thawed semen samples. Hum Reprod (1998) 0.90
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer (1998) 0.90
Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol (1995) 0.89
Induction of disabled-2 gene during megakaryocyte differentiation of k562 cells. Biochem Biophys Res Commun (2001) 0.89
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues. J Med Chem (1989) 0.87
The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Adv Enzyme Regul (1996) 0.87
Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression. Clin Cancer Res (1996) 0.86
Metabolism and disposition of the antifolate LY231514 in mice and dogs. Drug Metab Dispos (1997) 0.86
The osteogenic stimulating effect of neuroactive calcitonin gene-related peptide. Peptides (1990) 0.85
Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol (1999) 0.85
Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int J Gynaecol Obstet (2005) 0.85
Normal expression and the effects of ectopic expression of the Drosophila muscle segment homeobox (msh) gene suggest a role in differentiation and patterning of embryonic muscles. Dev Biol (1995) 0.84
Wrist injuries in adolescent gymnasts of a Chinese opera school: radiographic survey. Radiology (1995) 0.84
A successful pregnancy with in vitro fertilization and embryo transfer in an infertile woman with Kartagener's syndrome: a case report. J Assist Reprod Genet (1998) 0.84
Assessment of the relative locations of the greater palatine foramen in adult Chinese skulls. Acta Anat (Basel) (1988) 0.84
Effects of phenol feeding pattern on microbial community structure and cometabolism of trichloroethylene. Appl Environ Microbiol (1996) 0.83
Transactivation of the human MDR1 gene by hepatitis B virus X gene product. J Hepatol (1998) 0.82
Nanoparticle distribution during systemic inflammation is size-dependent and organ-specific. Nanoscale (2015) 0.82
Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Adv Enzyme Regul (1997) 0.82
MR imaging of articular cartilage in the ankle: comparison of available imaging sequences and methods of measurement in cadavers. Skeletal Radiol (1996) 0.82
The effects of brief gamete co-incubation in human in vitro fertilization. J Assist Reprod Genet (2000) 0.82
Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts. Anticancer Res (2002) 0.82
Mishaps of CPR: the case of the missing dental bridge. N Engl J Med (1982) 0.81
Suprasegmental and segmental timing models in Mandarin Chinese and American English. J Acoust Soc Am (2000) 0.81
Benefit of bilateral pallidotomy in the treatment of generalized dystonia. Case report. J Neurosurg (1999) 0.80
Investigation of pulsed low dose rate radiotherapy using dynamic arc delivery techniques. Phys Med Biol (2012) 0.80
A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr (2000) 0.80
Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer Chemother Pharmacol (2000) 0.80
Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts. Biochem Pharmacol (1996) 0.80
Embryonic dormancy phenomenon in obstructed healthy mouse fallopian tubes. J Assist Reprod Genet (2000) 0.80
Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet. Cancer Chemother Pharmacol (1998) 0.79
Separating X-bearing human spermatozoa through a discontinuous Percoll density gradient proved to be inefficient by double-label fluorescent in situ hybridization. J Assist Reprod Genet (1998) 0.79